JP2019509046A - Ｈｉｖ結合剤 - Google Patents

Ｈｉｖ結合剤 Download PDF

Info

Publication number
JP2019509046A
JP2019509046A JP2018548300A JP2018548300A JP2019509046A JP 2019509046 A JP2019509046 A JP 2019509046A JP 2018548300 A JP2018548300 A JP 2018548300A JP 2018548300 A JP2018548300 A JP 2018548300A JP 2019509046 A JP2019509046 A JP 2019509046A
Authority
JP
Japan
Prior art keywords
seq
amino acid
hiv
antibody
binding agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018548300A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019509046A5 (enExample
Inventor
パンタレオ，ジュゼッペ
ランザヴェッキア，アントニオ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute for Research in Biomedicine IRB
Centre Hospitalier Universitaire Vaudois CHUV
Original Assignee
Institute for Research in Biomedicine IRB
Centre Hospitalier Universitaire Vaudois CHUV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute for Research in Biomedicine IRB, Centre Hospitalier Universitaire Vaudois CHUV filed Critical Institute for Research in Biomedicine IRB
Publication of JP2019509046A publication Critical patent/JP2019509046A/ja
Publication of JP2019509046A5 publication Critical patent/JP2019509046A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2018548300A 2015-12-05 2016-12-05 Ｈｉｖ結合剤 Pending JP2019509046A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562263618P 2015-12-05 2015-12-05
US62/263,618 2015-12-05
PCT/IB2016/057367 WO2017093985A1 (en) 2015-12-05 2016-12-05 Hiv binding agents

Publications (2)

Publication Number Publication Date
JP2019509046A true JP2019509046A (ja) 2019-04-04
JP2019509046A5 JP2019509046A5 (enExample) 2020-01-23

Family

ID=57629603

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018548300A Pending JP2019509046A (ja) 2015-12-05 2016-12-05 Ｈｉｖ結合剤

Country Status (6)

Country Link
US (2) US10730933B2 (enExample)
EP (1) EP3383902A1 (enExample)
JP (1) JP2019509046A (enExample)
CN (1) CN108779168A (enExample)
CA (1) CA3045756A1 (enExample)
WO (1) WO2017093985A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022541900A (ja) * 2019-07-15 2022-09-28 ローザンヌ ユニヴァーシティ ホスピタル Ｈｉｖ結合剤

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10730933B2 (en) 2015-12-05 2020-08-04 Centre Hospitalier Universitaire Vaudois HIV binding agents
WO2020012435A1 (en) * 2018-07-13 2020-01-16 Lausanne University Hospital Hiv binding agents
WO2020082045A1 (en) * 2018-10-19 2020-04-23 University Of Maryland, College Park Multispecfic anti-hiv antibodies
CN115963260B (zh) * 2022-06-27 2025-05-23 珠海碳云晶芯智能科技有限公司 多肽芯片及其在艾滋病诊断产品制备中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10226699A (ja) * 1996-12-10 1998-08-25 Fujirebio Inc Ｈｉｖ−１グループｏを認識するモノクローナル抗体及び該モノクローナル抗体を産生するハイブリドーマ
JP2009080118A (ja) * 1996-10-10 2009-04-16 Probe Internatl ウイルス感染を処置するための組成物および方法
JP2012522520A (ja) * 2009-04-03 2012-09-27 デューク ユニバーシティー マウスモデル

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DK169582B1 (da) 1986-06-23 1994-12-12 Squibb Bristol Myers Co Humant monoklonalt antistof, der er i stand til at reagere med en epitop på LAV/HTLV-III kappeglycoproteinet gp41, cellelinier, som producerer sådant antistof, farmaceutisk præparat indeholdende antistoffet samt fremgangsmåde til bestemmelse af nærværelsen af LAV/HTLV-III i en biologisk prøve og fremgangsmåde til separering af specifikke antigendeterminanter af LAV/HTLV-III under anvendelse af ant
US5087557A (en) 1986-06-23 1992-02-11 Genetic Systems Corporation Human monoclonal antibody to lymphadenopathy-associated virus
EP0681026A1 (en) 1987-03-02 1995-11-08 Whitehead Institute For Biomedical Research Recombinant mycobacterial vaccine
US5504005A (en) 1987-03-02 1996-04-02 Albert Einstein College Of Medicine Of Yeshiva University Recombinant mycobacterial vaccine
ATE135743T1 (de) 1987-11-13 1996-04-15 Hermann Katinger Monoklonale menschliche antikörper gegen hiv-i
US5831034A (en) 1987-11-13 1998-11-03 Hermann Katinger Human monoclonal anti-HIV-I-antibodies
AU608413B2 (en) 1988-03-30 1991-03-28 Abbott Laboratories Mouse monoclonal antibody (5-21-3) to human immunodeficiency virus gp41 protein
US5298419A (en) 1988-03-31 1994-03-29 The Arizona Board Of Regents On Behalf Of The University Of Arizona Human hybridomas and monoclonal antibodies which bind both gp41 and gp120 envelope proteins of human immunodeficiency virus
JPH0292298A (ja) 1988-09-30 1990-04-03 Olympus Optical Co Ltd Ｈｉｖ構成蛋白に対するモノクローナル抗体
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
JPH04505099A (ja) 1989-02-28 1992-09-10 ニューヨーク　ユニバーシィティ ヒト免疫不全ウイルスに対するヒトモノクローン抗体
US5731189A (en) 1989-02-28 1998-03-24 New York University Human monoclonal antibodies to human immunodeficiency virus
WO1990014363A1 (en) 1989-05-19 1990-11-29 Amgen Inc. Metalloproteinase inhibitor
US6008044A (en) 1989-08-24 1999-12-28 Bioclonetics Human monoclonal antibodies directed against the transmembrane glycoprotein (gp41) of human immunodeficiency virus-1 (HIV-1) and detection of antibodies against epitope (GCSGKLIC)
US5459060A (en) 1989-08-24 1995-10-17 Bioclonetics Incorporated Human monoclonal antibodies directed against the transmembrane glycoprotein (gp41) of human immunodeficiency virus-1 (HIV-1)
EP0511300A4 (en) 1990-01-16 1993-05-26 Replgien Corporation Monoclonal antibody specific for non-immunodominant epitope of hiv proteins
WO1991013157A1 (en) 1990-02-26 1991-09-05 Commonwealth Scientific And Industrial Research Organisation Shuttle plasmid for escherichia coli and mycobacteria
GB9015888D0 (en) 1990-07-19 1990-09-05 Smithkline Biolog Vectors
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
CA2089661C (en) 1990-08-29 2007-04-03 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2110682A1 (en) 1991-06-06 1992-12-10 Charles K. Stover Induction of ctl responses to foreign antigens expressed in mycobacteria
DE570357T1 (de) 1992-05-14 1994-07-28 Polimun Scientific Immunbiologische Forschungsgesellschaft Mbh, Wien Peptide, die Antikörper induzieren, die genetisch divergierende HIV-1 Isolationen neutralisieren.
US5652138A (en) 1992-09-30 1997-07-29 The Scripps Research Institute Human neutralizing monoclonal antibodies to human immunodeficiency virus
US6057421A (en) 1994-11-30 2000-05-02 Immpheron, Inc. Variable heavy and light chain regions of murine monoclonal antibody 1F7
EP0822941B1 (en) 1995-04-19 2002-06-12 Polymun Scientific Immunbiologische Forschung GmbH Monoclonal antibodies against hiv-1 and vaccines made thereof
US20030118985A1 (en) 1997-05-14 2003-06-26 Hunt Jeffrey C. Mouse monoclonal antibody (5-21-3) to human immunodeficiency virus gp41 protein
EP1225907A4 (en) * 1999-10-05 2005-06-22 Epimmune Inc INDUCING CELLULAR IMMUNE RESPONSES TO HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS
CN1172717C (zh) 2000-08-18 2004-10-27 清华大学 一种治疗艾滋病的药物及其制备方法
KR20120004551A (ko) 2003-10-28 2012-01-12 어플라이드 머티어리얼스, 인코포레이티드 스크러버 박스 및 그 사용 방법
ATE516048T1 (de) 2004-06-01 2011-07-15 Merck Sharp & Dohme Mit hiv gp41 in wechselwirkung stehende menschliche antikörper
WO2006050219A2 (en) 2004-10-29 2006-05-11 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Broadly cross-reactive hiv-1 neutralizing human monoclonal antibodies
WO2011046623A2 (en) * 2009-10-16 2011-04-21 Duke University Hiv-1 antibodies
EP2611465A4 (en) 2010-08-31 2014-06-04 Theraclone Sciences Inc ANTIBODIES FOR NEUTRALIZING THE HUMAN IMMUNODICITY VIRUS (HIV)
BR112014010823B1 (pt) * 2011-11-07 2021-02-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services anticorpos que se ligam a gp41 e neutralizam o vírus da imunodeficiência humana tipo 1 (hiv-1), seus usos, molécula de ácido nucleico, vetor de expressão, composição, kit, bem como métodos de detecção de infecção pelo hiv-1 e de teste de imunógeno potencial
WO2015103549A1 (en) 2014-01-03 2015-07-09 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Neutralizing antibodies to hiv-1 env and their use
US10730933B2 (en) 2015-12-05 2020-08-04 Centre Hospitalier Universitaire Vaudois HIV binding agents

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009080118A (ja) * 1996-10-10 2009-04-16 Probe Internatl ウイルス感染を処置するための組成物および方法
JPH10226699A (ja) * 1996-12-10 1998-08-25 Fujirebio Inc Ｈｉｖ−１グループｏを認識するモノクローナル抗体及び該モノクローナル抗体を産生するハイブリドーマ
JP2012522520A (ja) * 2009-04-03 2012-09-27 デューク ユニバーシティー マウスモデル

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RETROVIROLOGY, vol. 3:42, JPN6020042521, 2006, ISSN: 0004536830 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022541900A (ja) * 2019-07-15 2022-09-28 ローザンヌ ユニヴァーシティ ホスピタル Ｈｉｖ結合剤
JP7678790B2 (ja) 2019-07-15 2025-05-16 ローザンヌ ユニヴァーシティ ホスピタル Ｈｉｖ結合剤

Also Published As

Publication number Publication date
WO2017093985A1 (en) 2017-06-08
CA3045756A1 (en) 2017-06-08
EP3383902A1 (en) 2018-10-10
US20190345234A1 (en) 2019-11-14
WO2017093985A4 (en) 2017-07-27
CN108779168A (zh) 2018-11-09
US20210009661A1 (en) 2021-01-14
US10730933B2 (en) 2020-08-04

Similar Documents

Publication Publication Date Title
US11130807B2 (en) Immunological reagents
ES3034233T3 (en) Non-blocking pd1 specific antibodies
US20210009661A1 (en) HIV Binding Agents
US20220411492A1 (en) Antibody against claudin 18a2 and use thereof
JP2024502046A (ja) Ｃｏｖｉｄ－１９に対する中和モノクローナル抗体
US20230272048A1 (en) Hiv-1 antibodies
WO2020012435A1 (en) Hiv binding agents
US20250312438A1 (en) Humanized constructs, vaccines, and methods
JP7678790B2 (ja) Ｈｉｖ結合剤
WO2023064435A2 (en) Compositions and methods relating to sars-cov-2 neutralizing antibodies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180703

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191205

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191205

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201111

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210212

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210412

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210630